iNewz.in Hindi News

Who Director General Tedros Adhanom Ghebreyesus Advice, Prioritize Covax, Maker Of Approved Vaccines, Not Shareholders Profit

PTI, Geneva.

Published by: Yogesh Sahu
Updated Fri, 05 Nov 2021 03:56 AM IST

WHO chief Tedros Adhanom Ghebreyesus
– Photo : WHO-iStock

World Health Organization (WHO) chief Dr. Tedros Adhanom Ghebreyesus on Thursday gave an advisory to manufacturers of anti-Covid-19 vaccines. He has said that manufacturers of vaccines that have received emergency use approval from the WHO should prioritize Covax over the profits of their shareholders.

WHO Director-General Tedros Adhanom Ghebreyesus made this remark a day after Bharat Biotech’s anti-Covid vaccine ‘Covaccine’ was approved for emergency use. He said during the media briefing about the corona virus that yesterday (Wednesday) we have included another vaccine. Covaccine is listed for emergency use. It is the eighth vaccine to receive WHO validation for safety, efficacy and quality.

He said that we will continue to call on manufacturers of vaccines listed for emergency use by WHO to prioritize Covax over the benefit of shareholders. He said that vaccines that have not yet received emergency use approval from the WHO should contact it and discuss how the process can be accelerated. COVAX is a global initiative that aims to provide equitable access to vaccines.

World Health Organization (WHO) chief Dr. Tedros Adhanom Ghebreyesus on Thursday gave an advisory to manufacturers of anti-Covid-19 vaccines. He has said that manufacturers of vaccines that have received emergency use approval from WHO should prioritize Covax over the profits of their shareholders.

WHO Director-General Tedros Adhanom Ghebreyesus made this remark a day after Bharat Biotech’s anti-Covid vaccine ‘Covaccine’ was approved for emergency use. He said during the media briefing about the corona virus that yesterday (Wednesday) we have included another vaccine. Covaccine is listed for emergency use. It is the eighth vaccine to receive WHO validation for safety, efficacy and quality.

He said that we will continue to call on manufacturers of vaccines listed for emergency use by WHO to prioritize Covax over the benefit of shareholders. He said that vaccines that have not yet received emergency use approval from the WHO should contact it and discuss how the process can be accelerated. COVAX is a global initiative that aims to provide equitable access to vaccines.

WHO Director General Tedros Adhanom Ghebreyesus advice, Prioritize Covax, maker of approved vaccines, not shareholders profit

.

Leave a Reply